bio:cap: New investor fair in Berlin connects science and capital!

bio:cap: New investor fair in Berlin connects science and capital!

The Charité – Universitätsmedizin Berlin and the Berlin Institute of Health in the Charité (BIH) have announced the initiation of a new event format called bio:cap. This international life science and AI investment aims to connect leading investors with start-ups, research institutions and companies in the areas of biotech, techbio and artificial intelligence (AI). The premiere of bio:cap will take place on June 2nd and 3rd, 2026 at the Berlin exhibition center Charité.de reported.

The event's target groups are innovative start-ups and companies from the biotech and pharmaceutical industries, investors, investor networks, the healthcare industry, research institutions as well as IT, AI and cloud providers. The format is intended to provide a platform for networking, investments and professional exchange at an international level.

Event details and partners

The name bio:cap is made up of the terms “biotechnology” and “capital”. The event is organized by Messe Berlin in partnership with the Charité and the BIH as well as the support of the Hasso Plattner Institute (HPI). The partners include the Investitionsbank Berlin (IBB) with IBB Ventures and the Investitionsbank des Landes Brandenburg (ILB).

bio:cap will place a strong focus on strategic matchmaking and present curated networking formats as well as high-quality content. In addition to start-up presentations, science-related keynotes, political discussions and the presentation of large funds are planned. One focus will be on the role of artificial intelligence in the life sciences.

An important location for innovations

Berlin is considered Germany's start-up capital. The capital attracts talent, capital and creativity from all over the world and, together with Brandenburg, forms one of the largest science clusters in Europe. This regional connection between entrepreneurial spirit and creative culture supports innovation in biotechnology, AI and digital health. Developments such as molecular diagnostics, personalized therapies and digital drug twins are noted Messe Berlin highlights.

The bio:cap is intended to act as a catalyst for investments in the life sciences and at the same time create a connection between politics and those involved in science, investments and pharmaceuticals. Berlin, as a political metropolis in the heart of Europe, offers the framework in which strategies for science and growth are developed. These conditions are crucial for investors and founders.

In addition, Berlin's inspiring backdrop, which combines historical flair, modern tech hubs and a lively nightlife, promotes openness and exchange, which are of great importance for international specialist events.

The bio:cap opens a new chapter in the capital's innovation history, opening up numerous opportunities for networking and developing new ideas in the field of life sciences.